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Abstract 
Millions of people die each year from infectious disease, and 
many more are affected by allergies.  A major stumbling block to 
the full use of improved immunotherapies (e.g. vaccines) against 
these problems is our limited ability to deliver genes and drugs to 
the required sites in the body.  Specifically, effective methods to 
deliver genes and drugs into outer skin and mucosal layers (sites 
with immunological, physical and practical advantages that 
cannot be targeted via traditional delivery methods) are lacking.  
This paper investigates this particular challenge for physical 
delivery approaches using fluid mechanics.  The skin structural 
and immunogenic properties are examined in the context of the 
physical cell targeting requirements of the viable epidermis.  
Selected current physical cell targeting technologies engineered 
to meet these needs are examined: needle and syringe; diffusion 
patches; liquid jet injectors; microneedle arrays/patches; and 
biolistic particle delivery.  The focus then moves to biolistic 
particle delivery: we first analyse engineering these systems to 
meet demanding clinical needs.   
 
Introduction  
The provision of safe and efficient routes of delivery of 
immunotherapeutics to the  immunologically sensitive dendritic 
cells in the skin (and mucosa) has the potential to enhance 
strategies in the treatment of major disease.  Examples of these 
include DNA vaccines and the immunotherapy of allergies.  The 
application of physical methods to achieving this goal presents 
unique engineering challenges in the physical transport of 
immunotherapeutic biomolecules (e.g. polynucleotides) to these 
cells. 
In this paper, the physiology, immunology and material 
properties of the skin are examined in the context of the physical 
cell targeting requirements of the viable epidermis.  Selected cell 
targeting technologies engineered to meet these needs are briefly 
presented.  The operating principles of these approaches are 
described, together with a discussion of their effectiveness for the 
non-invasive targeting of viable epidermis cells and the DNA 
vaccination against major diseases.  The focus then moves to one 
of these methods, called biolistics, that ballistically delivers 
millions of microparticles coated with biomolecules to outer skin 
layers.  The engineering of these devices is presented, beginning 
with earlier prototypes before examining a more advanced 
system configured for clinical use. 
 
Engineering of physical approaches for the targeting of 
skin and mucosal cells 
Within the viable epidermis, the location of Langerhans cells—as 
a delivery target for DNA vaccination—is tightly defined by: 
• a vertical position at a consistent suprabasal location [ 1]; 
• a spatial distribution in the horizontal plane evenly distributed 
throughout the skin ; and 
• a constitution of 2% of the total epidermal cell population. 
How can these and other epidermal skin cells be targeted?  
Despite its recognized potential, the viable epidermis has only 
recently been viewed as a feasible cellular targeting site with the 
emergence of new biological and physical technologies 
(discussed in detail in [ 2]).  The challenge is the effective 
penetration of the SC and precise targeting of the cells of interest. 
 
Mechanical properties of the stratum corneum physical barrier 
The SC is a semi-permeable barrier that—owing to its variable 
mechanical properties—is challenging to breach, in a minimally 
invasive manner, to target the viable epidermal cells below.  
Mechanically, the SC is classified as a bio-viscoelastic solid and 
shows highly variable properties.  Obvious differences include 
the huge variation in thickness and composition with the skin site 
and the age of an individual [ 3, 4].  However, there are more 
subtle and equally important variations in SC properties to 
consider when configuring targeting methods. 
As one example, the SC mechanical breaking stress is strongly 
influenced by the ambient humidity/moisture content [ 3]—the 
relative humidity range from 0% to 100% results in a decrease in 
excised human SC breaking stress from 22.5 MPa to 3.2 MPa  
Similarly, an increase in ambient temperature also results in an 
SC breaking stress decrease by an order of magnitude.  These and 
other sources of variability in the SC mechanical properties 
present challenges in configuring approaches to breach, in a 
minimally invasive manner, the SC and effectively deliver 
polynucleotides or antigens to the underlying cells. 
 
Physical cell targeting approaches 
Many physical technologies are being developed  to overcome 
some limitations of biological approaches using needle-free 
mechanisms to breach the SC barrier to facilitate drug and 
vaccine administration directly to epidermal cells.  Figure 1 
illustrates schematically key physical targeting approaches 
relative to the scale of typical skin and the Langerhans cell layer 
of interest.   
Needle and syringe (Figure 1a). For the illustration of the most 
common physical delivery method, a small gauge needle and 
syringe is shown in half-section in Figure 1a.  Although this 
approach easily breaches the SC, precise targeting of the 
Langerhans cell-rich viable epidermis cannot be practically 
achieved.  Hence, the needle and syringe is used for 
intramuscular injection.  This inefficient, indirect targeting of 
dendritic cells with DNA has resulted in modest immune 
responses [ 5]. Other disadvantages of the needle and syringe 
include risks due to needle-stick injuries and needle phobia. 
(a) Diffusion/permeation delivery (Figure 1b). Perhaps the least 
invasive method of breaching the SC is by permeation through it, 
driven by diffusion from patches applied to the skin [ 6].  
However, currently, the general view is that this mode of delivery 
is best suited to smaller biomolecules (<500 Da [ 6])—
considerably smaller than oligonucleotides and antigens.  This 
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view is being challenged, with a recent study showing that very 
large recombinant antigens of ~1 MDa can be delivered to elicit 
systemic responses by diffusion from patches .  The transport of 
larger biomolecules through the SC can be further enhanced by 
simple approaches, including tape stripping with an adhesive 
tape, brushing with sandpaper or the application of depilatory 
agents.  ,Amongst the more advanced technologies are 
electroporation, ablation by laser or heat, radiofrequency high-
voltage currents, iontopheresis, liposomes , sonophoresis and 
microporation  Many of these approaches remain untested for 
complex entities such as vaccines and immunotherapies.  
Permeation through the SC can also be enhanced by the coating 
of plasmid DNA on nanoparticles (~100 nm) for DNA 
vaccination. 
(b) Liquid jet injectors (Figure 1c). An earlier physical needle-
free approach with an initial interest in the mid-twentieth century 
was the high-speed liquid jet injector [ 7].  This technique has 
seen a recent resurgence, with liquid delivered around the 
Langerhans cells in gene transfer and DNA vaccination 
experiments [ 7], and the delivery of drugs [ 8].  As shown in 
Figure 1c, current liquid jet injectors typically disrupt the skin in 
the epidermal and dermal layer.  To target exclusively the viable 
epidermal cells, such as Langerhans cells, the challenge of more 
controlled delivery needs to be addressed. 
(c) Microneedle arrays/patches (Figure 1d). Researchers have 
overcome some of the disadvantages described by fabricating 
arrays of micrometre-scale projections to breach the SC and to 
deliver naked DNA to several cells in live animals [ 9].  Similar 
microprojection devices are used to increase the permeability of 
drugs and “conventional” protein antigen vaccines,.  Figure 1d 
shows that, unlike current liquid jet injectors, these microneedles 
can accurately target the viable epidermis.  Furthermore, they are 
as simple to use as patches, whilst overcoming the SC diffusion 
barrier to many molecules.  Moreover, compared with both the 
needle and syringe and liquid jet injectors, these microneedle 
methods are pain-free because of epidermal targeting.  By 
drawing upon a range of manufacturing techniques, McAllister et 
al.[ 10] have shown that these microneedle arrays can be 
fabricated cost effectively from a range of materials, including 
silicon, metal and biodegradable polymers.  These collective 
advantages make microneedle patches a very promising method 
of delivering oligonucleotides practically and cost effectively to 
epidermal cells for DNA vaccination.  Figure 2 shows an 
example of the micro-nanoprojection patch device used for this 
purpose within our research group. 
(d) Biolistic microparticle injection (Figure 1e).  Currently, the 
most established physical method of DNA vaccination is biolistic 
microparticle delivery, otherwise known as gene guns. 
In this needle-free technique, pharmaceutical or 
immunomodulatory agents, formulated as particles, are 
accelerated in a high-speed gas jet to sufficient momentum to 
penetrate the skin (or mucosal) layer and to achieve a 
pharmacological effect.  Biolistic DNA vaccination is achieved 
by the delivery of gold microspheres coated with plasmid DNA 
coding for specific antigens to epidermal dendritic cells [ 11].   
Contoured Shock Tube, was conceived and developed [ 12].  The 
devices operate with the principle of delivering a payload of 
microparticles to the skin with a narrow range of velocities, by 
entraining the drug payload in a quasi-one-dimensional, steady 
supersonic flowfield.  
 
In experiments with simple prototype CST devices, it was shown 
that the desired gas flow was achieved repeatedly.  Importantly, 
further work with particle payloads measured a variation in free-
jet particle velocity of ±4%.  In this research, measurements were 
made with Particle Image Velocimetry (PIV).   
 
An embodiment of the CST configured to meet clinical needs is 
shown in Fig. 3, with the key components labelled.  The device 
was fabricated from biocompatible materials and the device wall 
thickness was kept relatively constant to meet autoclave 
sterilization requirements. 
 
To reduce the overall system length, the bottle reservoir (which 
operates by an actuation pin) is located within the driver annulus.  
A challenge of this co-axial arrangement was to maintain 
integrity of transonic gas flow within the driver initiated after 
diaphragm rupture.  This challenge was met by carefully 
contouring the driver and obstacle of the mounting arrangement.  
Possible fragments from opening of the aluminium gas bottle are 
contained by a sealed filter at the bottle head. 
 
The powdered pharmaceutical is enclosed and sealed by a 
cassette created by the inclusion of additional diaphragms 
upstream of the particle payload.  In this case, the cassette houses 
two jets designed to mix the particles into a cloud, hence 
reducing the dependence on the initial particle location. 
Therefore, a nominally uniform spatial distribution of particles is 
released within the quasi-steady flow through the shock tube and 
nozzle.  Repeated in vitro and in vivo experiments show that 
polycarbonate diaphragm fragments do not damage the target. 
 
Elements of the silencing system are also shown in Fig. 3. The 
primary shock initiated by diaphragm rupture, reflected from the 
target, is identified as the main source of sound to be attenuated. 
This shock is collapsed into compression waves by a series of 
compressions–expansions induced by an array of orifices and 
saw-tooth baffles, resulting in appropriate sound levels for the 
operator and patient. 
 
The device lift-off force is also to be well within user constraints.  
A peak lift-off force of 13 N is achieved by the careful selection 
of endbell contact diameter, silencer volume, flowrates through 
the reservoir and silencer geometry. This peak was for only a 
very short time within a gas flow lasting only ~200 µs (with a 
helium driver gas).  The point of contact between the device and 
skin target was selected to maintain a target seal and to minimize 
the lift-off force, whilst not adversely affecting the impact 
velocities of the particles.  The effect of silencing was also 
minimized by maintaining a supersonic gas flow transporting 
particles through the nozzle—so changes in the nozzle boundary 
condition were not fed upstream. 
 
The range of impact conditions for the CST platform was 
achieved by the selection of appropriate helium/nitrogen mixtures 
within the gas bottle driver/driven area ratios. 
 
Figure 1e shows a representative schematic diagram of 
microparticles in the skin following biolistic delivery, mirroring 
the observed microparticle distributions in human skin [ 13] and 
porcine skin [ 3]. 
Careful engineering analysis and design of the gas–particle 
dynamics of hand-held biolistics devices  have led to advanced 
systems with nominally uniform and repeatable microparticle 
impact velocity distributions.  Owing to the range in 
microparticle size, there is a broader than ideal impact 
momentum per unit area distribution for the microparticles—a 
parameter shown to be important for targeting specific skin layers 
[ 3] and the mucosa. 
Because of this momentum variation, and the discussed large 
variability in tissue mechanical properties, a significant fraction 
of the microparticle payload does not breach the SC, as shown in 
Figure 1e.  Importantly, Figure 1e also shows that many 
microparticles do reach the viable epidermis, allowing the 
triggering of the direct transfection of Langerhans cells as well as 
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keratinocytes; this enables the antigen to be processed via the 
exogenous pathways, thereby generating a balanced immune 
response [ 2] for DNA vaccination.  Interesting recent work has 
shown that the action of ballistic particle penetration can lead to 
significant cell death in the skin [ 14].  These findings suggest that 
indirect, cross-priming transfection mechanisms take place in the 
skin, and these are the subject of further investigation.  The 
overall goal of this and our other biolistics research is to optimize 
the delivery of microparticles and local biological effects to 
provide a further enhanced and consistent physical DNA 
vaccination platform technology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 A schematic cross-section of the skin showing 
Langerhans cells.  Five physical cell targeting approaches are 
also shown.  (a) A half-section of a small gauge needle and 
syringe; (b) route of diffusion from patches; (c) penetration 
from a liquid jet injector; (d) a hole from a microinjector; 
and (e) distribution of microparticles following biolistic 
injection. 
 
 
 
 
 
Figure 2. A scanning electron micrograph of a micro-
nanoprojection patch following application to human skin. 
 
 
 
 
 
 
 
 
Figure 3.  A contoured shock tube (CST) prototype 
configured for clinical biolistic delivery 
 
References 
Langerhans cell ~10µm 
1-2mm
1. Hoath SB, Leahy DG. Formation and function of the stratum 
corneum. In: Marks R, Levenge J, Voegli R (eds.), The 
Essential Stratum Corneum. London: Martin Dunitz, 2002. 
2. Kendall MAF.  (2006) “Engineering of needle-free physical 
methods to target epidermal cells for DNA vaccination”, 
Vaccine May 22; 24(21): 4651—4656. 
3. Kendall MAF, Rishworth S, Carter FV, Mitchell TJ. The 
effects of relative humidity and ambient temperature on the 
ballistic delivery of micro-particles into excised porcine 
skin. J Invest Dermatol 2004; 122(3):739–746. 
4. Kendall, M.A.F. CHONG, Y. & COCK, A. The mechanical 
properties of the skin epidermis in relation to targeted gene 
and drug delivery. Biomaterials 2007; 28:4968 – 4977. 
5. Mumper RJ, Ledebur HC. Dendritic cell delivery of plasmid 
DNA: application for controlled nucleic acid-based 
vaccines. Mol Biotech 2001; 19:79–95. 
6. Glenn GM, Kenney RT, Ellingsworth LR, Frech SA, 
Hammond SA, Zoeteweweij JP. Transcutaneous 
immunization and immunostimulant strategies: capitalizing 
on the immunocompetence of the skin. Expert Rev Vaccines 
2003; 2(2):253–267. 
7. Furth PA, Shamay A, Henninghausen L. Gene transfer into 
mammalian cells by jet injection. Hybridoma 1995; 14:149–
152. 
8. Bremseth DL, Pass F. Delivery of insulin by jet injection: 
recent observations. Diabetes Technol Ther 2001; 3:225–
232. 
9. Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis 
RJ, Harvery NG. Improved genetic immunization via 
micromechanical disruption of skin-barrier function and 
targeted epidermal delivery. Nature 2002; 8(4):415–419. 
10. McAllister DV, Wang PM, Davis SP, Park JH, Canatella PJ, 
Allen MG, Prausnitz MR. Microfabricated needles for 
transdermal delivery of macromolecules and nanoparticles: 
fabrication methods and transport studies. Proc Natl Acad 
Sci USA 2003; 25(100):13755–13760. 
11. Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, 
Culp J, Burkholder JK, Swain WF, Dixon RM, Widera G, 
Vessey R, King A, Ogg G, Gallimore A, Haynes JR, 
Heydenburg Fuller D.. Induction of antigen-specific CD8+ 
T cells, T helper cells, and protective levels of antibody in 
humans by particle mediated administration of a hepatitis B 
virus DNA vaccine. Vaccine 2000; 19:764–778. 
12. Kendall MAF. The delivery of particulate vaccines and 
drugs to human skin with a practical, hand-held shock tube-
based system. Shock Waves J 2002; 12(1):22–30. 
13. Kendall MAF, Mitchell TJ, Wrighton-Smith P. Intradermal 
ballistic delivery of micro-particles into excised human skin 
for drug and vaccine applications. J Biomechanics 2004; 
37(11):1733–1741. 
14. Raju PA, Truong NK, Kendall MAF. Assessment of 
epidermal cell viability by near infra-red two-photon 
microscopy following ballistic delivery of gold micro-
particles. 
50-100µm
-20µm
Dermis
epidermis
able 
corneum
Stratum
(a)
(b)
(c) (d)
10
Vi
(e)
615
